OKYO Pharma Limited
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gary S. Jacob
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 55 Park Lane London United Kingdom W1K 1NA
- IPO Date
- Oct 9, 2020
- Website
- okyopharma.com
- Similar Companies
- Business
- OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage biopharmaceutical company focused on developing innovative GPCR-based therapies for ocular diseases with significant unmet medical needs, including neuropathic corneal pain, dry eye disease, allergic conjunctivitis, and uveitis. The company offers a pipeline of proprietary drug candidates, notably urcosimod (formerly OK-101), a lipid-conjugated chemerin peptide agonist that functions as a non-steroidal anti-inflammatory and non-opioid analgesic by targeting the ChemR23 G-protein coupled receptor to reduce inflammation and neuropathic pain in ocular tissues; OK-201, an agonist for MAS-Related G Protein-Coupled Receptor (MRGPR) aimed at acute and chronic ocular pain management via novel topical and nasal formulations; and earlier-stage discovery programs for additional non-opioid analgesics and ocular therapies. Founded in 2007 and headquartered in London, United Kingdom, with operations spanning the US and UK, OKYO Pharma targets patients suffering from inflammatory eye diseases and chronic ocular pain, particularly in markets like the $5 billion dry eye sector affecting over 700 million people worldwide. Recent developments include the initiation of a Phase 2 clinical trial for urcosimod in neuropathic corneal pain in Q3 2024, following completion of a Phase 2 trial for dry eye disease in Q4 2023 that demonstrated statistically significant results across multiple endpoints; FDA clearance of its investigational new drug application as the first for NCP; plans for a multiple-ascending-dose trial to identify optimal dosing ahead of pivotal studies; and share acquisitions by entities linked to Executive Chairman Gabriele Cerrone in 2025, increasing his holdings to over 10.4 million ordinary shares, signaling strong insider confidence.
Why Is OKYO Pharma (OKYO) Stock Down 19% Today?
OKYO Pharma inks collaboration with Tufts Medical Center
OKYO Pharma begins OK-101 phase 2 dosing
OKYO Pharma to address key conference with data on dry eye drug
OKYO Pharma screens first patient for dry eye disease trial
OKYO Pharma ready to kick off dry eye trial in the US
OKYO Pharma plans UK de-listing in favour of US quote
OKYO Pharma shares soar on news it is gearing up for dry eye disease treatment trial
Why Is Okyo Pharma (OKYO) Stock Up 13% Today?
OKYO Pharma starts trial process for dry eye disease treatment
Why Is OKYO Pharma (OKYO) Stock Down 10% Today?
Why Is OKYO Pharma (OKYO) Stock Down 31% Today?
OKYO Pharma making final preparations for upcoming clinical trial of dry eye disease drug
OKYO Pharma appoints leading US ophthalmology expert to its scientific board
Why Is OKYO Pharma (OKYO) Stock Down 19% Today?
OKYO Pharma eyes progress for OK-101 in 2023, releases interim results
OKYO Pharma receives US FDA license to start Phase 2 study
OKYO Pharma applies for the go ahead for phase II trial of its dry eye disease treatment
OKYO Pharma to work with AmbioPharm on dry eye IND filing
Okyo Pharma to focus on dry eye treatment in coming year